Last reviewed · How we verify
NKT-01
At a glance
| Generic name | NKT-01 |
|---|---|
| Also known as | Deoxyspergualin, gusperimus |
| Sponsor | Nippon Kayaku Co., Ltd. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Phase II Study on Gusperimus in Patients With Refractory Wegener's Granulomatosis (PHASE2)
- Safety and Efficacy on Deoxyspergualin (NKT-01) in Patients With Lupus Nephritis (PHASE1, PHASE2)
- Effectiveness of the Investigational Drug Campath-1H in Preventing Rejection of Transplanted Kidneys (PHASE2)
- Peritransplant Deoxyspergualin in Islet Transplantation in Type 1 Diabetes (PHASE2)
- Clinical Study Comparing the New Immunosuppressive Drug Gusperimus With the Conventional Treatment in Wegener's Granulomatosis (PHASE3)
- Efficacy and Safety of Deoxyspergualin in Renal Transplant Patient With Chronic Rejection (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- NKT-01 CI brief — competitive landscape report
- NKT-01 updates RSS · CI watch RSS
- Nippon Kayaku Co., Ltd. portfolio CI